Sun Pharma on Thursday reported 123 per cent year-on-year increase in consolidated net profit at Rs 894 crore for the quarter ending March 31, 2021. It was Rs 399.8 crore in the year-ago period.
However, the profit was still below the Street's expectation of over Rs 1,200 crore. Sun Pharma has incurred an exceptional loss of Rs 672.8 crore related to various litigation settlements pertaining to some of its subsidiaries.
Sun Pharma said the adjusted net profit came in at Rs 1,343 crore, up 103 per cent year-on-year.
Its revenue from operations came in at Rs 8,522 crore for the quarter under review, an increase of 4 per cent from Rs 8,184 crore in the same quarter last year.
India sales during the March quarter stood at Rs 2,670 crore, registering a growth of 12.9 per cent compared to previous year. Sale of branded formulations from India business accounted for 31.7 per cent of total sales.
US finished dosage sales at $370 million, decline of 1.3 per cent over same period last year.
Meanwhile, other income for the March quarter is at Rs 111 crore. At the operating level, earnings before interest, tax, deprecitation and amortisation (EBITDA) stood at Rs 1,956 crore, up by 55.8 per cent over last year, with a resulting margin of 23.2 per cent.
The company's board has recommended a final dividend of Rs 2 per share for the financial year ended March, 2021.
Ahead of the results, the company's scrip was down 0.47 per cent at Rs 700.5 on NSE.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU